New clinical practice guidelines emerge at such a speed that it is all but impossible for primary care physicians to keep up with medical developments. This has concerning implicat
Pharmaceutical companies provide one of the, if not the, most important products to HCPs - the medical advances that make a huge difference to patient outcomes. But bringing new me
The need for pharmaceutical companies to meet or, ideally exceed, the expectations their customers have of them is not new to the industry. Yet new research indicates that many in
The FDA has started a priority review of Bristol-Myers Squibb Opdivo in combination with cisplatin as a first-line therapy for advanced urothelial carcinoma (UC), setting
On 1st October, the roll-out of the National Contract Value Review (NCVR) process marked a pivotal moment in the trajectory of clinical research in the UK, introducing a standardised, natio